Briviact
Preclinical
UCBBriviact is one of 41 therapeutic programs targeting Epilepsy. It is currently in Preclinical.
1
Indications
0
Total Trials
0
Active Trials
40
Competitors
Pipeline
Status by Indication[1]
Competition
Competitive Landscape
221 competitors in Epilepsy
#DrugCompanyPhaseTrials
1Briviact
UCBPhase 3
Epidiolex
Jazz PharmaceuticalsPhase 3
Dayvigo
EisaiPhase 3
Depacon
AbbViePhase 3
Zonegran
AAzurity Pharmaceuticals
Phase 3
Actemra
RochePhase 3
Fintepla
IImmedica Pharma AB
Phase 3
Deltavit
HHyundai Pharmaceutical Co., LTD.
Phase 3
Narcan
SScienture
Phase 3
GWP42003-P
Jazz PharmaceuticalsPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Sources
References
- [1]Open Targets Platform — Drug–disease associations for Briviact. EMBL-EBI & Wellcome Sanger Institute.
- [2]
Details
Drug Info
Quick Facts
- Highest Phase
- Preclinical
- Company